Design of 20-deoxyingenol-esters-based PKC agonists and their lysosome biogenesis-enhancing activity
Jiajia Wan(Hainan University), Ying‐Tong Di(Kunming Institute of Botany), Bowen Ouyang(Kunming Institute of Botany), Ming-Rui Yuan(Kunming Institute of Botany), Mao Sun(Anshun University), Ding‐Kang Chen(Kunming Institute of Botany), Xiao-Jiang Hao(Kunming Institute of Botany), Cui‐Shan Zhang(Kunming Institute of Botany), Zifei Xu(Kunming Institute of Botany), Peng‐Fei Yao(Kunming Institute of Botany), Mingming Cao(Kunming Institute of Botany), Qun Chen(Virginia Commonwealth University), Hao‐Jing Zang(Kunming Institute of Botany), Chong‐Lin Yang(Yunnan University), Qiuyuan Yin(Kunming Institute of Botany)
Cited by 2
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Protein kinase C controls lysosome biogenesis independently of mTORC1
|Nature Cell Biology|2016|359
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
CDK4/6 regulate lysosome biogenesis through TFEB/TFE3
|The Journal of Cell Biology|2020|109